153 related articles for article (PubMed ID: 34493151)
1. Effects of ruxolitinib on infection in patients with myeloproliferative neoplasm: a meta-analysis.
Luo Q; Xiao Z; Peng L
Hematology; 2021 Dec; 26(1):663-669. PubMed ID: 34493151
[TBL] [Abstract][Full Text] [Related]
2. Ruxolitinib-associated infections: A systematic review and meta-analysis.
Lussana F; Cattaneo M; Rambaldi A; Squizzato A
Am J Hematol; 2018 Mar; 93(3):339-347. PubMed ID: 29150886
[TBL] [Abstract][Full Text] [Related]
3. Risk factors for infections and secondary malignancies in patients with a myeloproliferative neoplasm treated with ruxolitinib: a dual-center, propensity score-matched analysis.
Tremblay D; King A; Li L; Moshier E; Coltoff A; Koshy A; Kremyanskaya M; Hoffman R; Mauro MJ; Rampal RK; Mascarenhas J
Leuk Lymphoma; 2020 Mar; 61(3):660-667. PubMed ID: 31711337
[TBL] [Abstract][Full Text] [Related]
4. [Safety and Effectiveness of Ruxolitinib for Treatment of Myeloproliferative Neoplasm: A Meta-Analysis].
Yang ZR; Zhu HY
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2018 Apr; 26(2):493-501. PubMed ID: 29665922
[TBL] [Abstract][Full Text] [Related]
5. Safety and efficacy of combined ruxolitinib and decitabine in accelerated and blast-phase myeloproliferative neoplasms.
Rampal RK; Mascarenhas JO; Kosiorek HE; Price L; Berenzon D; Hexner E; Abboud CN; Kremyanskaya M; Weinberg RS; Salama ME; Menghrajani K; Najfeld V; Sandy L; Heaney ML; Levine RL; Mesa RA; Dueck AC; Goldberg JD; Hoffman R
Blood Adv; 2018 Dec; 2(24):3572-3580. PubMed ID: 30563881
[TBL] [Abstract][Full Text] [Related]
6. Myeloproliferative neoplasms treated with hydroxyurea, pegylated interferon alpha-2A or ruxolitinib: clinicohematologic responses, quality-of-life changes and safety in the real-world setting.
Gill H; Leung GMK; Yim R; Lee P; Pang HH; Ip HW; Leung RYY; Li J; Panagiotou G; Ma ESK; Kwong YL
Hematology; 2020 Dec; 25(1):247-257. PubMed ID: 32567517
[No Abstract] [Full Text] [Related]
7. Risk of viral reactivation in patients with occult hepatitis B virus infection during ruxolitinib treatment.
Gill H; Leung GMK; Seto WK; Kwong YL
Ann Hematol; 2019 Jan; 98(1):215-218. PubMed ID: 29946910
[No Abstract] [Full Text] [Related]
8. Impaired response to first SARS-CoV-2 dose vaccination in myeloproliferative neoplasm patients receiving ruxolitinib.
Guglielmelli P; Mazzoni A; Maggi L; Kiros ST; Zammarchi L; Pilerci S; Rocca A; Spinicci M; Borella M; Bartoloni A; Rossolini GM; Annunziato F; Vannucchi AM
Am J Hematol; 2021 Nov; 96(11):E408-E410. PubMed ID: 34331712
[No Abstract] [Full Text] [Related]
9. Risk of hepatitis B virus reactivation following ruxolitinib treatment in patients with myeloproliferative neoplasms.
Duan MH; Cao XX; Chang L; Zhou DB
Hematology; 2021 Dec; 26(1):460-464. PubMed ID: 34184610
[TBL] [Abstract][Full Text] [Related]
10. Outcomes and characteristics of nonmelanoma skin cancers in patients with myeloproliferative neoplasms on ruxolitinib.
Rampotas A; Carter-Brzezinski L; Somervaille TCP; Forryan J; Panitsas F; Harrison C; Witherall R; Innes AJ; Wallis L; Butt NM; Psaila B; Mead AJ; Carter M; Godfrey AL; Laing H; Garg M; Francis S; Ewing J; Teh CH; Cowen HB; Dyer P; McConville C; Wadelin F; Sahra A; McGregor A; Kulakov E; McLornan DP; Lambert J
Blood; 2024 Jan; 143(2):178-182. PubMed ID: 37963262
[TBL] [Abstract][Full Text] [Related]
11. Safety and efficacy of ruxolitinib in splanchnic vein thrombosis associated with myeloproliferative neoplasms.
Pieri L; Paoli C; Arena U; Marra F; Mori F; Zucchini M; Colagrande S; Castellani A; Masciulli A; Rosti V; De Stefano V; Betti S; Finazzi G; Ferrari ML; Rumi E; Ruggeri M; Nichele I; Guglielmelli P; Fjerza R; Mannarelli C; Fanelli T; Merli L; Corbizi Fattori G; Massa M; Cimino G; Rambaldi A; Barosi G; Cazzola M; Barbui T; Vannucchi AM
Am J Hematol; 2017 Feb; 92(2):187-195. PubMed ID: 27880982
[TBL] [Abstract][Full Text] [Related]
12. Ruxolitinib in clinical practice for primary and secondary myelofibrosis: an analysis of safety and efficacy of Gruppo Laziale of Ph-negative MPN.
Breccia M; Andriani A; Montanaro M; Abruzzese E; Buccisano F; Cedrone M; Centra A; Villivà N; Celesti F; Trawinska MM; Massaro F; Di Veroli A; Anaclerico B; Colafigli G; Molica M; Spadea A; Petriccione L; Cimino G; Latagliata R
Ann Hematol; 2017 Mar; 96(3):387-391. PubMed ID: 27889820
[TBL] [Abstract][Full Text] [Related]
13. Does ruxolitinib improve survival of persons with MPN-associated myelofibrosis? Should it?
Barosi G; Zhang MJ; Gale RP
Leukemia; 2014 Nov; 28(11):2267-70. PubMed ID: 25027516
[No Abstract] [Full Text] [Related]
14. Determinants of Covid19 disease and of survival after Covid19 in MPN patients treated with ruxolitinib.
Palandri F; Elli EM; Auteri G; Bonifacio M; Benevolo G; Heidel FH; Paglia S; Trawinska MM; Bosi C; Rossi E; Tiribelli M; Tieghi A; Iurlo A; Polverelli N; Caocci G; Binotto G; Cavazzini F; Beggiato E; Cilloni D; Tatarelli C; Mendicino F; Miglino M; Bocchia M; Crugnola M; Mazzoni C; Romagnoli AD; Rindone G; Ceglie S; D'Addio A; Santoni E; Cattaneo D; Bartoletti D; Lemoli RM; Krampera M; Cuneo A; Semenzato GC; Latagliata R; Abruzzese E; Vianelli N; Cavo M; Andriani A; De Stefano V; Palumbo GA; Breccia M
Blood Cancer J; 2023 May; 13(1):65. PubMed ID: 37137878
[No Abstract] [Full Text] [Related]
15. Patient with eosinophilic dermatosis of myeloproliferative disease presenting with generalized erythematous plaques - Response to Ruxolitinib.
Sun Y; Hsiao HH; Lan CE
Australas J Dermatol; 2021 Nov; 62(4):e613-e615. PubMed ID: 34490892
[No Abstract] [Full Text] [Related]
16. Improvement of the hematologic toxicities of ruxolitinib in patients with MPN-associated myelofibrosis using a combination of thalidomide, stanozolol and prednisone.
Duan M; Zhou D
Hematology; 2019 Dec; 24(1):516-520. PubMed ID: 31242816
[No Abstract] [Full Text] [Related]
17. Safety of Janus Kinase Inhibitors in Patients With Inflammatory Bowel Diseases or Other Immune-mediated Diseases: A Systematic Review and Meta-Analysis.
Olivera PA; Lasa JS; Bonovas S; Danese S; Peyrin-Biroulet L
Gastroenterology; 2020 May; 158(6):1554-1573.e12. PubMed ID: 31926171
[TBL] [Abstract][Full Text] [Related]
18. Therapy for myeloproliferative neoplasms: when, which agent, and how?
Geyer HL; Mesa RA
Blood; 2014 Dec; 124(24):3529-37. PubMed ID: 25472969
[TBL] [Abstract][Full Text] [Related]
19. Underlying mechanisms of the JAK2V617F mutation in the pathogenesis of myeloproliferative neoplasms.
Mullally A
Pathologe; 2016 Nov; 37(Suppl 2):175-179. PubMed ID: 27796499
[TBL] [Abstract][Full Text] [Related]
20. Long-term efficacy and safety of ruxolitinib versus best available therapy in polycythaemia vera (RESPONSE): 5-year follow up of a phase 3 study.
Kiladjian JJ; Zachee P; Hino M; Pane F; Masszi T; Harrison CN; Mesa R; Miller CB; Passamonti F; Durrant S; Griesshammer M; Kirito K; Besses C; Moiraghi B; Rumi E; Rosti V; Blau IW; Francillard N; Dong T; Wroclawska M; Vannucchi AM; Verstovsek S
Lancet Haematol; 2020 Mar; 7(3):e226-e237. PubMed ID: 31982039
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
